TALAPORFIN SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H37N5O9.4Na
Molecular Weight	799.6876
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].CCC1=C(C)C2=CC3=C(C=C)C(C)=C(N3)C=C4N=C([C@@H](CCC([O-])=O)[C@@H]4C)C(CC(=O)N[C@@H](CC([O-])=O)C([O-])=O)=C5NC(=CC1=N2)C(C)=C5C([O-])=O

InChI

InChIKey=KPALSRNVSRWOPA-YJFNSWLASA-J

InChI=1S/C38H41N5O9.4Na/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24;;;;/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52);;;;/q;4*+1/p-4/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-;;;;/t18-,22-,30-;;;;/m0..../s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20001435
Curator's Comment: description was created based on several sources, including http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). Talaporfin is injected into tumors and other regret tissues where it accumulates. It’s activated with light emitting diodes (LED). It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength. It was approved in Japan (in 2004) for PDT of lung cancer and glioma and marketed as Laserphyrin. Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lung cancer 69 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26888042	Primary		Approved 8429	Unknown Approved Use Unknown
Malignant glioma 10 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26888042	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

single intravenous injection of talaporfin sodium (40 mg/m(2)) was administered 1 day before resection of the neoplasm

Route of Administration: Intravenous

In Vitro Use Guide

combination of 30 µg/mL NPe6 (talaporfin sodium) with 5 J/cm(2) laser is the best treatment condition for inducing an increase in apoptotic cells while keeping rate of necrotic cell death low

Name

Type

Language

TALAPORFIN SODIUM

Official Name

English

ME-2906

Code

English

Tetrasodium (2S)-2-[[[(7S,8S)-3-carboxylato-7-(2-carboxylatoethyl)-13-ethenyl-18-ethyl-2,8,12,17-tetramethyl-7,8-dihydroporphyrin-5-yl]acetyl]amino]butanedioate

Common Name

English

TALAPORFIN SODIUM [USAN]

Common Name

English

ME 2906

Code

English

LS-11

Code

English

TALAPORFIN SODIUM [MART.]

Common Name

English

TALAPORFIN TETRASODIUM SALT [MI]

Common Name

English

TALAPORFIN SODIUM [JAN]

Common Name

English

Talaporfin sodium [WHO-DD]

Common Name

English

L-ASPARTIC ACID, N-(((7S,8S)-3-CARBOXY-7-(2-CARBOXYETHYL)-13-ETHENYL-18-ETHYL-7,8-DIHYDRO-2,8,12,17-TETRAMETHYL-21H,23H-PORPHIN-5-YL)ACETYL)-, TETRASODIUM SALT

Common Name

English

LASERPHYRIN

Brand Name

English

TALAPORFIN TETRASODIUM SALT

Common Name

English

TAPORFIN SODIUM

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1420